CD274 and non-small cell lung carcinoma: For the second‐line setting, Keynote 01019 suggested that pembrolizumab significantly improved the objective response rate (ORR), PFS and OS among patients with advanced NSCLC and PD‐L1 TPS ≥1% (Table 1).